Among tested patients, the frequency of MSI-H, BRAF wild type CRC patients at-risk of LS was equivalent in 2022–2023 (139/2466; 5.6%) and 2021–2022 (122/2236; 5.5%; p = 0.52), but was higher in 2019–2020 (61/601; 10.2%; p = 5.1 × 10–4) (Table 1), likely due to more selective testing. Here, BRAF is linked to colorectal carcinoma.